Prescription ·Strong evidence ·Reviewed May 2026
Vancomycin is a glycopeptide antibiotic used to treat serious Gram-positive infections, most notably methicillin-resistant Staphylococcus aureus (MRSA). It is given intravenously for systemic infections and orally for Clostridioides difficile (C. difficile) infection, where the oral form stays in the gut and is not meaningfully absorbed. Because of its narrow therapeutic window and potential for kidney and ear toxicity, intravenous use typically requires therapeutic drug monitoring.
The bottom line
Evidence rating strong. Most-documented uses: treatment of methicillin-resistant staphylococcus aureus (mrsa) infections, treatment of clostridioides difficile (c. difficile) infection (oral), serious gram-positive infections in patients allergic to beta-lactams. 3 sources indexed (2011–2020), with 4 interaction records on file.
Core mechanism
Vancomycin inhibits bacterial cell wall synthesis by binding with high affinity to the D-alanyl-D-alanine terminal of peptidoglycan precursor units. This binding sterically blocks transglycosylase and transpeptidase enzymes from incorporating these precursors into the growing cell wall, preventing cross-linking and elongation. The result is a weakened cell wall that leads to bacterial lysis and death. It is bactericidal against most Gram-positive organisms and acts at a different site than beta-lactam antibiotics, which is why it remains effective against methicillin-resistant strains.3,1
Oral vancomycin is very poorly absorbed from the gastrointestinal tract, which is intentional for treating C. difficile because it keeps the drug acting locally in the colon. Systemic infections therefore require the intravenous route. Oral dosing can be taken without regard to meals.
Nutrients this medication can lower over time, and what to replace.
Vancomycin nephrotoxicity, particularly with intravenous use, elevated trough concentrations, or concurrent aminoglycosides, can cause acute kidney injury and renal tubular dysfunction that promotes urinary magnesium wasting.
Vancomycin-associated acute kidney injury and renal tubular injury can impair potassium reabsorption and lead to renal potassium loss; this is largely a consequence of nephrotoxicity rather than a direct nutrient-binding effect.
Oral vancomycin used to treat Clostridioides difficile infection suppresses the colonic bacteria that synthesize menaquinone (vitamin K2), which can modestly reduce endogenous vitamin K availability; clinically this is most relevant in patients with poor dietary intake or on warfarin.
Vancomycin can suppress or kill bacterial probiotic organisms if taken at the same time, although selected probiotics may lower antibiotic-associated diarrhea risk.
Recommendation: Separate probiotic doses from the antibiotic by at least 2 hours when feasible; avoid probiotic use in severely immunocompromised patients or patients with central lines unless clinician-directed.
Creatine can raise measured serum creatinine and complicate renal assessment for Vancomycin, which depends on kidney function for dosing or toxicity monitoring.
Recommendation: Tell the prescriber about creatine use and avoid creatine loading during acute illness, kidney injury, or therapy requiring close renal dosing.
Intravenous vancomycin is nephrotoxic, particularly at high troughs or with prolonged courses, and renal impairment alters the clearance and balance of magnesium. Significant supplemental magnesium in a patient with vancomycin-associated acute kidney injury can accumulate and cause hypermagnesemia. There is no direct chemical interaction, but renal monitoring is warranted.
Recommendation: Patients on IV vancomycin, especially prolonged or high-dose courses, should have renal function and serum magnesium monitored. Avoid high-dose magnesium supplementation in the setting of reduced kidney function unless directed by a clinician. Oral vancomycin (minimal systemic absorption) does not meaningfully interact with magnesium.
High-dose intravenous or oral vitamin C is being studied and used in some critical-care protocols. Because intravenous vancomycin is cleared renally and can be nephrotoxic, very high doses of vitamin C (which is metabolized partly to oxalate and can stress the kidneys, especially in renal impairment) warrant caution when used alongside nephrotoxic antibiotics. Standard dietary or supplemental doses pose no meaningful concern.
Recommendation: Routine vitamin C supplementation at typical doses (up to about 1000 mg/day) is compatible with vancomycin. Avoid sustained gram-level (megadose) vitamin C in patients receiving IV vancomycin who have or are at risk for kidney injury, given the theoretical additive renal/oxalate burden. Maintain hydration and renal monitoring.
Numbered references. Citations throughout the page link here.
AUC-guided dosing (target AUC/MIC of 400-600) is recommended over trough-only monitoring to optimize efficacy and minimize acute kidney injury.
Oral vancomycin (or fidaxomicin) is recommended for both initial and recurrent C. difficile infection in place of metronidazole.
Vancomycin is recommended as a primary treatment option for a range of MRSA infections, with dosing guidance and monitoring considerations.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
